Company
Cosette
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
23
17 still marketed
Novel approvals
6
Approvals since 2021
3
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Evoxac approved Oct 15, 2026
- Welchol new use Oct 20, 2021
- Zipsor new use May 25, 2021
- Vyleesi (Autoinjector) approved NovelJun 21, 2019
- Welchol approved Apr 3, 2019
- Sympazan approved Nov 1, 2018
- Effient new use Priority reviewOrphanJul 12, 2016
- Welchol new use Jan 22, 2014
- Effient new use Oct 16, 2013
- Otrexup approved Oct 11, 2013
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (17)
Newest FDA action first.
- Vyleesi (Autoinjector) Bremelanotide Acetate · 2019
- Evoxac Cevimeline Hydrochloride · 2026
- Benicar Hct Hydrochlorothiazide, Olmesartan Medoxomil · 2003
- Indocin Indomethacin · 1985
- Sprix Ketorolac Tromethamine · 2010
- Cambia Diclofenac Potassium · 2009
- Zipsor Diclofenac Potassium · 2009
- Sympazan Clobazam · 2018
- Ambien Cr Zolpidem Tartrate · 2005
- Ambien Zolpidem Tartrate · 1992
- Welchol Colesevelam Hydrochloride · 2009
- Welchol Colesevelam Hydrochloride · 2000
- Effient Prasugrel Hydrochloride · 2009
- Azor Amlodipine Besylate, Olmesartan Medoxomil · 2007
- Tribenzor Amlodipine Besylate, Hydrochlorothiazide, Olmesartan Medoxomil · 2010
- Benicar Olmesartan Medoxomil · 2002
- Evoxac Cevimeline Hydrochloride · 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.